Lawrence K. Kvols
#152,413
Most Influential Person Now
Lawrence K. Kvols's AcademicInfluence.com Rankings
Lawrence K. Kvolsmedical Degrees
Medical
#2941
World Rank
#3387
Historical Rank
Oncology
#200
World Rank
#206
Historical Rank

Lawrence K. Kvolsphilosophy Degrees
Philosophy
#8486
World Rank
#11876
Historical Rank
Logic
#5515
World Rank
#6920
Historical Rank

Download Badge
Medical Philosophy
Why Is Lawrence K. Kvols Influential?
(Suggest an Edit or Addition)Lawrence K. Kvols's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. (1986) (835)
- Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms (1991) (815)
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas (2011) (666)
- Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial (2010) (647)
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. (2004) (561)
- Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. (1993) (538)
- Hepatic resection for metastatic neuroendocrine carcinomas. (1995) (456)
- Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. (1990) (390)
- Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. (2005) (376)
- Cytoreductive hepatic surgery for neuroendocrine tumors. (1990) (358)
- Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. (1981) (324)
- Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. (2002) (319)
- Peptide Receptor Radionuclide Therapy (2004) (317)
- Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. (2005) (294)
- The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. (2010) (294)
- Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. (2005) (291)
- Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. (2006) (289)
- NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. (2009) (275)
- The glucagonoma syndrome. Clinical and pathologic features in 21 patients. (1996) (267)
- Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma (2007) (256)
- Distribution of somatostatin receptors in normal and tumor tissue. (1990) (226)
- A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. (1982) (219)
- Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. (2011) (219)
- 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion (2003) (216)
- Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors (2006) (212)
- External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer (1988) (197)
- Outcome of cardiac surgery for carcinoid heart disease. (1995) (187)
- Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. (1993) (182)
- Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. (2012) (175)
- Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. (1993) (167)
- Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. (2005) (161)
- Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. (1989) (159)
- Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). (1987) (157)
- Rapid reversal of carcinoid crisis with a somatostatin analogue. (1985) (154)
- Multifocal inflammatory leukoencephalopathy with 5‐fluorouracil and levamisole (1992) (151)
- Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut (2009) (150)
- Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors: An Analysis of the AJCC and ENETS Staging Classifications (2012) (146)
- Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. (2006) (144)
- Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. (2013) (141)
- Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors (2011) (139)
- Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. (2009) (131)
- Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience (2014) (122)
- Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Colon and Rectum Tumour/Carcinoma (2007) (117)
- Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. (2005) (114)
- Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group (2006) (108)
- Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. (1979) (108)
- Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer. (1987) (104)
- GEPNETs update: Radionuclide therapy in neuroendocrine tumors. (2014) (104)
- Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. (2010) (103)
- In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. (1992) (103)
- In vitro detection of somatostatin receptors in human tumors. (1992) (103)
- A Phase II study of high‐dose paclitaxel in patients with advanced neuroendocrine tumors (2001) (102)
- Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. (1987) (100)
- Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. (1995) (94)
- A phase I clinical trial of recombinant human tumor necrosis factor (1988) (93)
- Treatment of the Malignant Carcinoid Syndrome (1987) (92)
- Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. (1977) (91)
- Metastatic carcinoid tumors and the malignant carcinoid syndrome. (1993) (90)
- Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. (1995) (88)
- Testicular neoplasms: 29 tumors studied by high-resolution US. (1985) (87)
- Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors (2011) (86)
- Somatostatin receptors in malignant tissues (1990) (84)
- Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia (1994) (82)
- 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model (2006) (81)
- Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors (1997) (81)
- Metastatic cancer to the testes: a report of 20 cases and review of the literature. (1989) (79)
- Rothmund‐Thomson syndrome in siblings: evidence for acquired in vivo mosaicism (1996) (78)
- Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. (2008) (78)
- A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. (2011) (76)
- OctreoTherTM: Ongoing Early Clinical Development of a Somatostatin-Receptor-Targeted Radionuclide Antineoplastic Therapy (2000) (75)
- Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. (1986) (73)
- Expression of somatostatin receptors in childhood neuroblastoma. (1994) (72)
- Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. (1993) (69)
- A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. (1994) (67)
- Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. (2005) (66)
- Synchronous and metachronous bilateral testicular tumors mayo clinic experience (1990) (62)
- Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing's syndrome. (1990) (62)
- Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine Carcinomas (2009) (62)
- Somatostatin receptors in human renal cell carcinomas. (1992) (61)
- The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. (1992) (61)
- Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. (2006) (59)
- In vitro detection of somatostatin receptors in human tumors. (1992) (59)
- A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome (1991) (58)
- Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors (2007) (58)
- In vitro and in vivo detection of somatostatin receptors in human malignant tissues. (1991) (58)
- Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. (2007) (57)
- Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. (1996) (56)
- Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? (2008) (56)
- Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. (2014) (55)
- Chemotherapy of endocrine malignancies: a review. (1987) (55)
- Therapy of the malignant carcinoid syndrome. (1989) (53)
- Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. (2004) (53)
- Chemotherapy of metastatic carcinoid and islet cell tumors. A review. (1987) (53)
- VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. (1978) (50)
- Carcinoid disease of the heart. Surgical management of ten patients. (1992) (49)
- Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. (2006) (48)
- Metastatic Carcinoid Tumors and the Malignant Carcinoid Syndrome (1994) (47)
- Intraoperative and external beam irradiation with or without resection: Mayo pilot experience. (1984) (44)
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. (2012) (42)
- Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. (2012) (39)
- Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma (1988) (38)
- Therapeutic considerations for the malignant carcinoid syndrome. (1989) (37)
- The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. (2006) (35)
- A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours (2007) (34)
- The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. (2010) (34)
- Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial (2015) (34)
- A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. (2013) (34)
- Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. (1993) (34)
- Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. (2010) (34)
- Pasireotide ( SOM 230 ) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study (2012) (33)
- Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. (1997) (33)
- Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. (2008) (33)
- High-resolution ultrasonographic and pathologic abnormalities of germ cell tumors in patients with clinically normal testes. (1983) (32)
- Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. (1994) (31)
- Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. (1979) (31)
- A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate (1990) (31)
- Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. (2009) (30)
- Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung. (1979) (27)
- Primary signet ring cell adenocarcinoma of the bladder. (1989) (27)
- First-Line Treatment of Metastatic Pancreatic Endocrine Carcinomas With Capecitabine and Temozolomide (2008) (26)
- Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. (2006) (26)
- Transtracheal selective bronchial brushing for pulmonary infiltrates in patients with cancer. (1976) (26)
- Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy (2007) (25)
- MRI of Pancreatic Islet Cell Carcinoma (1993) (25)
- Multimodality Management of “Borderline Resectable” Pancreatic Neuroendocrine Tumors (2017) (24)
- Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. (1997) (24)
- RUNX1T1: A Novel Predictor of Liver Metastasis in Primary Pancreatic Endocrine Neoplasms (2010) (23)
- Familial testicular cancer: report of six cases and review of the literature. (1990) (23)
- Phase I trial of parenteral 6-thioguanine given on 5 consecutive days. (1986) (21)
- A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer. (1985) (21)
- Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series (2013) (20)
- Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors. (2002) (20)
- Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide (2008) (20)
- 213 Bi-[ DOTA 0 , Tyr 3 ] Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical AnimalModel (2006) (19)
- Residual, recurrent, or unresectable gastrointestinal cancer. Role of radiation in single or combined modality treatment (1985) (19)
- Occult primary. (2008) (18)
- A phase II study of recombinant human alpha‐interferon in advanced hormone‐refractory prostate cancer (1992) (18)
- Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. (1986) (18)
- Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. (1981) (16)
- Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma. (1978) (15)
- Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR (2005) (15)
- Local control and survival in locally advanced gastrointestinal cancer. (1986) (15)
- Phase II evaluation of AMSA in patients with metastatic lung cancer. (1980) (15)
- Revisiting C.G. Moertel's land of small tumors. (2008) (15)
- Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. (2007) (15)
- Phase I–II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma (1991) (15)
- Phase II evaluation of PALA in patients with metastatic lung cancer. (1981) (14)
- A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. (1980) (14)
- Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. (1986) (14)
- Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma (2008) (14)
- A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy (1990) (14)
- Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? (1997) (14)
- Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure (1985) (14)
- Treatment of Liver Metastases in Patients with Neuroendocrine Tumors (2012) (13)
- Clinical Trial of Cisplatin and Intensive Course 5‐Fluorouracil for the Treatment of Advanced Colorectal Cancer (1986) (13)
- Medical oncology considerations in patients with metastatic neuroendocrine carcinomas. (1994) (13)
- Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy? (1994) (13)
- Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study (2001) (12)
- Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer. (1979) (12)
- Evaluation of a fixed alternating treatment in patients with advanced breast cancer. (1978) (12)
- Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma. (1984) (12)
- in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (2006) (12)
- Effect of the somatostatin analogue octreotide acetate on hemostasis in humans. (1991) (11)
- The carcinoid syndrome: a treatable malignant disease. (1988) (11)
- External beam vs. intraoperative and external beam irradiation for locally advanced pancreatic cancer (1986) (11)
- Indications for and results of intraoperative irradiation for locally advanced colorectal cancer. (1991) (11)
- Gastroenteropancreatic neuroendocrine tumours contain a common set of synaptic vesicle proteins and amino acid neurotransmitters. (1993) (10)
- Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer. (1987) (10)
- Reduced uncertainty as a diagnostic benefit: an initial assessment of somatostatic receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumours. (1998) (10)
- Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study. (2000) (10)
- Dosimetry and biodistribution of an iodine-123-labeled somatostatin analog in patients with neuroendocrine tumors. (1992) (10)
- Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. (2008) (10)
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. (2012) (10)
- Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. (2011) (10)
- Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer. (1984) (9)
- Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. (1978) (9)
- Phase I study of recombinant leukocyte a interferon (IFN‐α2A, roferon‐A) with doxorubicin in advanced malignant disease (1989) (9)
- Phase I Study of Difluoromethylornithine in Combination with Recombinant α2a-Interferon (1988) (9)
- Advances in the use of somatostatins in the management of endocrine tumors. (1996) (9)
- Cytoplasmic Clusterin Expression Correlates With Pancreatic Neuroendocrine Tumor Size and Pathological Stage (2013) (9)
- Molecular and cell biological aspects of gastroenteropancreatic neuroendocrine tumor disease (1994) (9)
- Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy. (2000) (8)
- Factor IX deficiency and bleeding in a patient with Sheehan's syndrome. (1972) (8)
- The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery (1974) (8)
- Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced sarcomas. (1984) (8)
- Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. (1987) (8)
- CARClNOlD SYNDROME SECONDARY TO A PRIMARY TUMOUR IN A MECKEL'S DIVERTICULUM (1993) (8)
- Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors (2003) (8)
- An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. (1981) (7)
- Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung. (1980) (7)
- Stage I nonfunctioning neuroendocrine tumors of the pancreas: Surgery or surveillance? (2011) (7)
- Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites. (1989) (7)
- Rebound hypergastrinemia after cessation of a somatostatin analogue (SMS 201-995) in malignant gastrinoma. (1987) (7)
- Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer. (1981) (6)
- Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report. (1977) (6)
- Metabolic effects of amino acids (AA) solutions infused for renal radioprotection. (2000) (6)
- Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon. (1988) (6)
- Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer. (1981) (6)
- Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. (2002) (6)
- Nuclear medicine imaging of breast cancer. (1996) (6)
- External beam irradiation of myocardial carcinoid metastases: a case report (2007) (6)
- Phase II trial of iv 6-thioguanine in advanced colorectal carcinoma. (1981) (6)
- Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))? (2000) (6)
- A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors. (2012) (6)
- Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer. (1981) (5)
- Elevated neuropeptide levels decrease during liver transplant. (1993) (5)
- Radionuclide therapy in neuroendocrine tumors (2014) (5)
- Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR (2010) (5)
- Peptide receptor radionuclide therapy (PRRT) with Y-90-DOTA(0),Tyr(3)-octreotide (Y-Oc) and In-111-DTPA(0)-octreotide (In-Oc): Comparison of tumor response and toxicity. (2002) (5)
- Neoplasms of the Diffuse Endocrine System (2003) (5)
- Carcinoid syndrome secondary to a primary tumour in a Meckel's diverticulum. (1993) (5)
- Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (2010) (5)
- Amino acid (AA) solutions infused for renal radioprotection: Metabolic effects (2000) (4)
- Phase II evaluation of triazinate in patients with metastatic lung cancer. (1980) (4)
- Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors. (2011) (4)
- Molecular genetics of neuroendocrine tumors (1993) (4)
- Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas. (1979) (4)
- Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma. (1983) (4)
- Tu1564 Predictors of Lymph Node Metastases and Impact on Survival in Resected Pancreatic Neuroendocrine Tumors, a Single Center Experience (2013) (4)
- Lymphocele after retroperitoneal node dissection for testis tumor (1986) (3)
- Effect of peptide amount on biodistribution of Y-86-DOTA-Tyr(3)-octreotide (SMT487). (2000) (3)
- Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma. (1979) (3)
- Chemotherapeutic sensitivity of minimal residual disease following surgical excision of ovarian carcinoma. (1978) (3)
- Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2. (2011) (3)
- Carcinoids of the Appendix (2004) (3)
- 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 11-13, 2015, Barcelona, Spain: Abstracts (2015) (3)
- Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma (1989) (3)
- Somatostatin Receptors in Gastroenteropancreatic Tumors (1996) (2)
- Occult primary cancer clinical practice guidelines. (2005) (2)
- Clinicopathologic analysis of well, moderately and poorly differentiated gastroenteropancreatic neuroendocrine tumors (2007) (2)
- 213Bi[Dota0, Tyr3]octreotide (Bi-DOTATOC) in peptide receptor radionuclide therapy (PRRT): Radiolabelling, stability and biodistribution (1999) (2)
- Octreotide LAR in carcinoid: how to dose? (2008) (2)
- A comparison of intra-arterial and cuff blood pressure measurements in very obese subjects. (1969) (2)
- Phase II study of maytansine in advanced breast cancer. (1981) (2)
- Incidental diagnosis of pancreatic neuroendocrine tumors. (2011) (2)
- Novel progression-associated genes in pancreatic endocrine neoplasms (2008) (2)
- Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma. (1980) (2)
- Parathyroid carcinomas, pheochromocytomas, and multiple endocrine neoplasia syndromes (2003) (2)
- Men 2A, 2B, and Non-Men Familial Medullary Thyroid Carcinoma (2003) (2)
- Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma. (1988) (2)
- Multimodality management of borderline resectable pancreatic neuroendocrine tumors: Sentinel report of a single-institutional experience. (2015) (2)
- Cancer: Principles & Practice of Oncology (1986) (2)
- Endocrine Neoplasms of the Gastroenteropancreatic (GEP) System (2003) (2)
- Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma. (1983) (1)
- Is there a role for octreotide in the treatment of hormone-refractory prostate cancer? (2002) (1)
- VP-16 in advanced squamous cell and adenocarcinoma of the lung (1978) (1)
- Phase II trial of diaziquone in advanced upper aerodigestive cancer. (1985) (1)
- Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA,Tyr3]octreotide: Toxicity and efficacy of 4-cycle and single-cycle regimens. (2004) (1)
- Octreotide use in patients with metastatic pancreatic neuroendocrine tumors. (2011) (1)
- Bisantrene phlebitis may be related to intravascular deposition of drug (1982) (1)
- Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
- Diagnosis in oncology (1998) (1)
- RUNXT1 and Palladin Outperform Pathologic Criteria of Malignancy in Predicting Liver Metastases in Primary Pancreatic Endocrine Carcinomas (2010) (1)
- Palladin is a Reliable Marker of Liver Metastasis in Primary Pancreatic Endocrine Neoplasms (2010) (1)
- Preface (1994) (0)
- Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure. (1983) (0)
- Adoption of neuroendocrine tumor (NET) research into treatment guidelines: Are rare cancers neglected? (2010) (0)
- Contents Vol. 85, 2007 (2007) (0)
- ENETS News Letter (2015) (0)
- Clinical and Echocardiographic Spectrum in 74 Patients: Carcinoid Heart Disease (1993) (0)
- NEUROENDOCRINE TUMORS (2007) (0)
- Carcinoid syndrome. (1998) (0)
- Platinum base polychemotherapy versus dianhydrogalactitol (DAG) in advanced non small cell lung cancer (NSCLC) (1977) (0)
- Metastasis-Associated Gene Products and Liver Metastases in Pancreatic Endocrine Tumors (2010) (0)
- Recent Advances in the Pathogenesis of Pancreatic Endocrine Neoplasms (2010) (0)
- Risk of metastatic spread in patients with early-stage, surgically resected pancreatic neuroendocrine tumors. (2011) (0)
- 213BI-[DOTA0,TYR3]OCTREOTIDE (Bi-DOTATOC) IN PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT): RADIOLABELING, STABILITY, AND BIODISTRIBUTION. (1999) (0)
- Contents Vol. 97 (2013) (0)
- Front & Back Matter (2012) (0)
- ENDSTAGE LIVER DISEASE (ESLD) PATIENTS HAVE ELEVATED NEUROPEPTIDE (NP) LEVELS WHICH FALL AFTER SUCCESSFUL LIVER TRANSPLANTATION (LT) (1993) (0)
- Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study. (2003) (0)
- Molecular Pathology and Diagnostics of Pancreatic Endocrine Neoplasms (2014) (0)
- Dr O'Connor and colleagues respond (1994) (0)
- Role of immunohistochemistry in the diagnosis of poorly differentiated neuroendocrine carcinoma. (2010) (0)
- Potential use of OctreoScan-111 to predict kidney exposure during 90Y-SMT487 therapy (2000) (0)
- Pharmacokinetic study of ADAH in humans and sensitivity of ADAH to light (1982) (0)
- Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer. (1981) (0)
- Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. (2004) (0)
- Subject Index Vol. 85, 2007 (2007) (0)
- Subject Index, Vol. 54, Supplement 1, 1993 (1993) (0)
- Prognostic relevance of a novel AJCC staging classification for neuroendocrine tumors of the pancreas. (2011) (0)
- patients with advanced neuroendocrine tumors refractory or resistant to (2012) (0)
- Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease. Conference proceedings. Berlin, Germany, November 3-7, 1993. (1994) (0)
- Peptide Receptor Analysis in Neuroendocrine Gastroenteropancreatic Tumors (1994) (0)
- Occult primary: Clinical practice guidelines in oncology (2008) (0)
- The Role of Somatostatin Receptor Scintigraphy in Gastroenteropancreatic Endocrine Tumors (1994) (0)
- Subject Index Vol. 11, 1994 (1994) (0)
- Sa1568 Diagnostic Performance of EUS-FNA for Cystic and Non Cystic Pancreatic Neuro-Endocrine Tumors: Single Center Experience From the Moffitt Cancer Center (2012) (0)
- Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases. (2016) (0)
- Somatostatin receptors in apudomas: A physiological basis for therapy and a diagnostical tumour marker (1989) (0)
- Phase II study of 9–10 anthracene‐dicarboxaldehyde bis(4,5‐dihydro-1 H‐imidazol-2‐yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma (1983) (0)
- Books Received in November-December 1980 / Book Reviews (1981) (0)
- Discovery and Validation of a Novel Set of Putative Progression Markers in Well-Differentiated Primary Pancreatic Endocrine Carcinomas (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Lawrence K. Kvols?
Lawrence K. Kvols is affiliated with the following schools: